Myriad Pharmaceuticals, Inc. Sets Date for Special Stockholder Meeting to Approve Merger with Javelin Pharmaceuticals

SALT LAKE CITY, March 15, 2010 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals Inc. (Nasdaq:MYRX), announced today that a registration statement on Form S-4 relating to the proposed merger with Javelin Pharmaceuticals, Inc. has been declared effective by the Securities and Exchange Commission and mailing of the joint proxy statement/prospectus contained therein will commence shortly.
MORE ON THIS TOPIC